Clinical Centre, Medical Faculty, University of Nis, Bul Zorana Djindjica 81 Nis, Serbia.
Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia and Dpt. of Clinical and Experimental Science, University of Brescia, Italy.
Autoimmun Rev. 2017 May;16(5):548-554. doi: 10.1016/j.autrev.2017.03.002. Epub 2017 Mar 6.
To collect data on vitamin D (25(OH)D) serum levels in a large number of rheumatoid arthritis (RA) patients from different European countries, to investigate their relation with disease activity, disability, quality of life, and possibly to construct a new Patient Reported Outcome (PRO) questionnaire in order to self-estimate if they are at risk for vitamin D insufficiency/deficiency-related clinical implications (D-PRO).
This was a European League Against Rheumatism (EULAR) supported cross-sectional study (project No CLI064) which involved 625 RA patients (mean age 55±11years, mean disease duration 11±9years), 276 age and sex matched healthy subjects, and rheumatologists working in academic institutions or hospital centres, as well as PARE organizations (patient representatives) from 13 European countries. Serum samples for 25(OH)D level measurement were collected during winter time and analyzed in a central laboratory using chemiluminescence immunoassay (DiaSorin). Patient past medical history was recorded. RA patients were provided with three questionnaires: the Rheumatoid Arthritis Impact Diseases score (RAID), the Health Assessment Questionnaire (HAQ), and the new D-PRO questionnaire at the time of 25(OH)D serum sampling. D-PRO questionnaire consisted of three domains, Symptom Risk Score (SRS), Habitus Risk Score (HRS) and Global Risk Score (SRS+HRS=GRS), constructed with items possibly related to vitamin D deficiency. D-PRO was correlated with both clinical and PRO scores. DAS28-CRP was also evaluated. Statistical analysis was performed by non parametric tests.
Mean serum concentration of 25(OH)D in RA patients (17.62±9.76ng/ml) was found significantly lower if compared to the levels obtained in matched controls (18.95±9.45ng/ml) (p=0.01), with statistically significant differences among several European countries. Negative correlations were found between 25(OH)D serum levels and DAS28-CRP (p<0.001), RAID (p=0.05) and HAQ (p=0.04) scores in the RA patients group. Negative correlations were also found in the cohort of enrolled RA patients between 25(OH)D serum concentrations and SRS (p=0.04), HRS (p=0.02) and GRS (p=0.02) domains of the D-PRO questionnaire.
This first multicentre European survey add new evidences that vitamin D insufficiency/deficiency is frequent in RA patients with statistically significant differences among several countries. Vitamin D serum concentrations seem to correlate negatively and significantly with the D-PRO Global Risk Score, clinimetric indexes for quality of life, disease activity and disability in present cohort of RA European patients.
收集大量来自不同欧洲国家的类风湿关节炎 (RA) 患者的维生素 D(25(OH)D)血清水平数据,研究其与疾病活动度、残疾、生活质量的关系,并可能构建一个新的患者报告结局 (PRO) 问卷,以便自我评估是否存在维生素 D 不足/缺乏相关临床意义(D-PRO)的风险。
这是一项由欧洲抗风湿病联盟 (EULAR) 支持的横断面研究(项目编号 CLI064),共纳入 625 例 RA 患者(平均年龄 55±11 岁,平均病程 11±9 年)、276 名年龄和性别匹配的健康对照者,以及来自 13 个欧洲国家的学术机构或医院中心的风湿病学家和 PARE 组织(患者代表)。在冬季采集血清样本用于 25(OH)D 水平检测,并在中央实验室使用化学发光免疫分析法(DiaSorin)进行分析。记录患者的既往病史。RA 患者在采集 25(OH)D 血清样本时,还接受了三个问卷的评估:类风湿关节炎影响疾病评分(RAID)、健康评估问卷(HAQ)和新的 D-PRO 问卷。D-PRO 问卷由三个部分组成,即症状风险评分(SRS)、习惯风险评分(HRS)和全球风险评分(SRS+HRS=GRS),这些部分由可能与维生素 D 缺乏相关的项目构成。D-PRO 与临床和 PRO 评分相关。还评估了 DAS28-CRP。通过非参数检验进行统计分析。
与匹配的对照组(18.95±9.45ng/ml)相比,RA 患者的 25(OH)D 血清浓度(17.62±9.76ng/ml)明显降低(p=0.01),且在多个欧洲国家之间存在统计学差异。在 RA 患者组中,25(OH)D 血清水平与 DAS28-CRP(p<0.001)、RAID(p=0.05)和 HAQ(p=0.04)评分呈负相关。在纳入的 RA 患者队列中,25(OH)D 血清浓度与 D-PRO 问卷的 SRS(p=0.04)、HRS(p=0.02)和 GRS(p=0.02)领域也呈负相关。
这是第一项多中心欧洲调查,提供了新的证据,表明维生素 D 不足/缺乏在 RA 患者中很常见,且在多个国家之间存在统计学差异。维生素 D 血清浓度与 D-PRO 全球风险评分、生活质量、疾病活动度和残疾的临床指标呈显著负相关。